We were honoured to participate in the official launch of the Targeted Translation Research Accelerator (TTRA) Drugs & Devices Program in Melbourne.
The event brought together the full cohort of 14 companies, alongside our impact partners CSL and Roche Diagnostics Australia, united by a shared mission to advance innovative drugs and devices addressing the growing global burden of diabetes and cardiovascular disease.
ProGenis Pharmaceuticals is proud to be part of this national initiative, working in collaboration with MTPConnect and our fellow cohort members to accelerate the translation of promising research into real-world solutions that improve the lives of patients, families, and communities.
We look forward to contributing to this important effort to strengthen Australia’s biomedical innovation ecosystem and deliver transformative RNA-based therapies for chronic diseases.